New Drug Pricing and Market Access

Back Bay Life Science Report

Treść dostarczona przez Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.

3y ago 26:25

MP3•Źródło odcinka

In this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisors to discuss how pharmaceutical companies price their drugs. They cover the ins and outs of health economics, how payers make sense of a high price, and ways this varies around the globe.

With a focus on Biogen’s recent Aduhelm approval, the discussion includes how Biogen likely went about price setting and how this aligns with ICER’s initial evaluation and analysis.

Topics in this podcast include:

Relevant pricing analogs
Net level pricing decisions
Demand and utilization of products affecting pricing
Patient population levels
ICER’s role in drug pricing
The price point of a drug, given its controversial approval

Read Back Bay’s perspective on early-stage market access and price setting in STAT News, here.

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

28 odcinków

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech